Windlas BiotechNSE:WINDLAS +0.94%89 PB Ratio is 3.14 as of Jun. 25, 2026, which is 46% above its 10-year median of 2.15. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹936.76 (Fairly Valued). The stock has 1 warning sign investors should review. Among 922 Drug Manufacturers companies, Windlas Biotech ranks worse than 70.72% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Windlas Biotech's share price is ₹863.80. Windlas Biotech's Book Value per Share for the quarter that ended in Mar. 2026 was ₹275.20. Hence, Windlas Biotech's PB Ratio of today is 3.14.
Good Sign:
Windlas Biotech Ltd stock PB Ratio (=2.97) is close to 2-year low of 2.77.
The historical rank and industry rank for Windlas Biotech's PB Ratio or its related term are showing as below:
NSE:WINDLAS'
s PB Ratio Range Over the Past 10 Years
Min: 1.17 Med: 2.15 Max: 5.07
Current: 3.14
During the past 8 years, Windlas Biotech's highest PB Ratio was 5.07. The lowest was 1.17. And the median was 2.15.
NSE:WINDLAS's PB Ratio is ranked worse than 70.72% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs NSE:WINDLAS: 3.14
During the past 12 months, Windlas Biotech's average Book Value Per Share Growth Rate was 14.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 20.40% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Windlas Biotech was 33.30% per year. The lowest was 10.00% per year. And the median was 26.00% per year.
Back to Basics: PB Ratio
Windlas Biotech (NSE:WINDLAS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Windlas Biotech PB Ratio Related Terms
Windlas Biotech PB Ratio Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Windlas Biotech's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Windlas Biotech (NSE:WINDLAS) has a PB Ratio of 3.14 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Windlas Biotech and its competitors. This is 46% above median its historical median of 2.15. Over the past decade, Windlas Biotech's PB Ratio has ranged from 1.17 to 5.07. According to the industry distribution chart, Windlas Biotech ranks #652 out of 922 companies in the Drug Manufacturers industry, placing it in the top 70.7%.
Is Windlas Biotech's PB Ratio too high?
Windlas Biotech's current PB Ratio of 3.14 is 46% above median its 10-year median of 2.15. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 5.07. The Drug Manufacturers industry median PB Ratio is 1.86. Windlas Biotech's value of 3.14 is 69.3% above this industry median. Based on the distribution chart, Windlas Biotech ranks #652 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #652 out of 922 companies for PB Ratio. This places Windlas Biotech in the lower half of its industry. The industry median PB Ratio is 1.86. Windlas Biotech's value of 3.14 is 69.3% above this benchmark. Historically, Windlas Biotech's own PB Ratio has ranged from 1.17 to 5.07 over the past decade. While the company's 10-year median is 2.15 vs. the industry median of 1.86, Windlas Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current PB Ratio of 3.14 is 69.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current PB Ratio is 3.14, which is 46% above median its own 10-year median of 2.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹936.76, compared to a current price of ₹863.80 — trading 7.8% below its estimated fair value. The current PB Ratio is 3.14, which is 46% above median its 10-year median of 2.15 and 69.3% above the Drug Manufacturers industry median of 1.86. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current PB Ratio is 3.14 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹863.80 is trading 7.8% below its estimated GF Value™ of ₹936.76.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
PB Ratio: 3.14 (46% above median its 10-year median of 2.15)
GF Value™: ₹936.76 vs. price of ₹863.80 (7.8% below fair value)
Industry Position: 69.3% above the Drug Manufacturers median (#652 of 922)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score
Get the complete analysis for NSE:WINDLAS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
